CSIMarket
 
Prelude Therapeutics Inc  (NASDAQ: PRLD)
Other Ticker:  
 
 
Price: $0.8611 $-0.07 -7.159%
Day's High: $0.95 Week Perf: -21.72 %
Day's Low: $ 0.84 30 Day Perf: -8.1 %
Volume (M): 170 52 Wk High: $ 6.80
Volume (M$): $ 146 52 Wk Avg: $2.06
Open: $0.93 52 Wk Low: $0.61



 Market Capitalization (Millions $) 65
 Shares Outstanding (Millions) 76
 Employees 17
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -128
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) 1

Prelude Therapeutics Inc
Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops innovative small molecule therapies for the treatment of cancer and other serious diseases. The company was founded in 2016 and is headquartered in Wilmington, North Carolina, with additional offices in New York City and Shanghai.

Prelude Therapeutics Inc. focuses on developing therapies that target signaling pathways that are critical for cancer growth and progression. The company's lead product candidate, PRT543, is a potent and selective inhibitor of PRMT5, an enzyme that is essential for the growth and survival of several types of cancer cells. PRT543 has shown promising preclinical activity in a variety of solid tumors and hematological malignancies, including diffuse large B-cell lymphoma, multiple myeloma, and acute myeloid leukemia.

In addition to PRT543, Prelude Therapeutics Inc. has a pipeline of other small molecule inhibitors that target key oncogenic signaling pathways, including Wnt, Notch, and Hedgehog. The company's approach is based on the belief that using a combination of targeted agents that attack different pathways may lead to more effective and durable responses in patients with cancer.

Prelude Therapeutics Inc. has a team of experienced pharmaceutical executives and scientists who have a track record of developing successful cancer therapies. The company has also established collaborations with leading academic and research institutions to accelerate the discovery and development of new therapeutics.

Overall, Prelude Therapeutics Inc. is a promising biopharmaceutical company that is focused on developing innovative therapies for the treatment of cancer and other serious diseases. With a robust pipeline of small molecule inhibitors and a team of experienced scientists and executives, the company has the potential to make a significant impact in the field of oncology.


   Company Address: 175 Innovation Boulevard Wilmington 19805 DE
   Company Phone Number: 467-1280   Stock Exchange / Ticker: NASDAQ PRLD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.6%    
BMY   -7.6%    
JNJ   -3.79%    
LLY   -3.33%    
MRK   -3.09%    
TEVA   -3.67%    
• View Complete Report
   



Clinical Study

Prelude Therapeutics Balancing Oncological Innovation with Financial Sustainability in the Era of Precision Medicine...

Published Fri, Apr 25 2025 9:18 PM UTC

Prelude Therapeutics Inc: A New Chapter in Targeted Cancer Therapies Amid Financial Challenges and Promising Preclinical Data Prelude Therapeutics Inc, a biotechnology company dedicated to transforming the treatment landscape for patients with cancer, recently announced the presentation of preclinical data on PRT3789 at the 2025 American Association for Cancer Research (AACR...

Clinical Study

Prelude Therapeutics Advances Novel Cancer Therapies with Promising Clinical Trial Results and Strategic s

Published Mon, Dec 30 2024 1:49 AM UTC

Prelude Therapeutics, a leader in developing targeted therapies for various malignancies, has reported encouraging preliminary results from ongoing clinical trials involving two of its key investigational compounds, PRT2527 and PRT3789. These compounds aim to address unmet medical needs in relapsed/refractory lymphoid malignancies and SMARCA4-mutated solid tumors, respect...

Clinical Study

Prelude Therapeutics Set to Present PRT3789 at EORTC-NCI-AACR Symposium A Potential Breakthrough in Targeting SMARCA2...

Published Wed, Oct 9 2024 11:30 AM UTC

Prelude Therapeutics Inc. is poised to make a significant impact in the field of oncology with its novel therapeutic candidate, PRT3789, which is set to be presented at the prestigious 36th EORTC-NCI-AACR Symposium on October 24, 2024. This symposium, an essential gathering in cancer research, will host a plenary session where Prelude will unveil findings regarding PRT3789, ...

Clinical Study

The Dual Narrative of Prelude Therapeutics Promising Clinical Advancements and Market Performance Challenges

Published Fri, Sep 13 2024 2:00 PM UTC

Prelude Therapeutics Inc. has recently garnered attention within the pharmaceutical sector due to their innovative therapeutic approach targeting cancer through the degradation of the SMARCA2 protein. Notably, their investigational drug, PRT3789, demonstrated promising initial clinical activity and a favorable safety profile in its Phase 1 trial, especially among patients wi...

Stocks on the Move

Prelude Therapeutics Inc Paving the Path in Precision Oncology

Published Fri, Jul 19 2024 3:44 PM UTC

Prelude Therapeutics Inc (PRLD) Stock: A SWOT AnalysisThe stock of Prelude Therapeutics Inc (NASDAQ: PRLD) has experienced a significant increase of 14.86% compared to its last closing price of 3.97. Despite this recent surge, the company has also seen a gain of 26.67% in its stock price over the past year. In this article, we will conduct a SWOT analysis of Prelude Therapeu...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com